Loading patent…
AssigneeGlaxo Group Limited
InventorsBarry C. Ross, David Middlemiss, David I. C. Scopes, Torquil I. M. Jack, Kevin S. Cardwell, Michael D. Dowle, John G. Montana, Martin Pass, Duncan B. Judd
Estimating the term…
The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt, solvate or metabolically labile ester thereof wherein R.sup.1 represents a hydrogen atom or a halogen atom or a group selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, fluoroC.sub.1-6 alkyl, C.sub.1-6 alkoxy, --CHO, --CO.sub.2 H or --COR.sup.2 ; Ar represents optionally substituted phenyl Het represents the group ##STR2## A represents ##STR3## The compounds may be used in the treatment or prophylaxis of hypertension and diseases associated with cognitive disorders.
A compound of formula (I):
A compound of formula (I) ##STR36## or a physiologically acceptable salt, solvate or metabolically labile ester thereof wherein
A compound of formula (I) ##STR40## or a physiologically acceptable salt, solvate or metabolically labile ester thereof wherein
A compound selected from
N-[2- [3-Bromo-5-[(5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-b enzofuranyl]phenyl]trifluoromethanesulphonamide or a physiologically acceptable salt or solvate thereof.
A compound of formula (I):
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
No related US applications are recorded in the indexed filing history.
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having…:…
Drugs for disorders of the metabolism: for glucose homeostasis
Drugs for disorders of the cardiovascular system
Drugs for disorders of the cardiovascular system: antihypertensives
Term ended 15 May 2012 (estimated)
USPTO file history isn’t available for this patent, so only indexed dates are shown.
This invention relates to benzofuran derivatives, processes for their preparation and pharmaceutical compositions containing them. According to a first aspect of the invention we provide a compound of the general formula (I): ##STR4## or a physiologically acceptable salt, solvate (e.g. hydrate) or metabolically labile ester thereof in which
R.sup.1 represents a hydrogen atom or a halogen atom or a group selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, fluoroC.sub.1-6 alkyl, C.sub.1-6 alkoxy, --CHO, --CO.sub.2 H or --COR.sup.2 ;
Ar represents the group ##STR5## R.sup.2 represents a group selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.1-6 alkoxy or the group --NR.sup.15 R.sup.16 ;
Conc. HCl (0.4 ml) was added to a suspension of Intermediate 7 (1 g) in methanol (25 ml). The solid gradually dissolved and after 15 min the solution was concentrated xn vacuo at 0.degree.. The resultant crystals (220 mg) were filtered off and the filtrate added to water (75 ml). The white precipitate was filtered off washed with water, THF and ether and dried to give the title compound.
Assay Found: C,59.7; H, 4.7; N, 14.5, C.sub.27 H.sub.23 BrN.sub.6 O. H.sub.2 O.0.5 C.sub.4 H.sub.8 O requires C, 59.9; H, 5.0; N, 14.45.
T.l.c. System C (200:8:1) Rf 0.60.